Carvolix SA is a French clinical-stage medical technology company specializing in the development of AI-based mini-robots and biomimetic implants for cardiovascular treatments. Formed in early 2026 through the merger of Affluent Medical with Caranx Medical and Artedrone, it focuses on revolutionizing transcatheter aortic valve replacement (TAVR) and stroke care. Key products include the TAVIPILOT Software, an AI-driven guidance system with FDA clearance obtained in July 2025 for real-time intra-operative support, and the TAVIPILOT Robot, designed for precise, autonomous valve positioning to enhance procedural accuracy and accessibility. These innovations address unmet needs in structural heart diseases, targeting markets valued at over €23 billion by 2030, where currently only a fraction of patients receive treatment due to procedural complexity. Headquartered in Aix-en-Provence, France, and founded in 2011 with roots in Affluent Medical, Carvolix SA employs around 76 people and operates in the healthcare supplies sector, integrating micro-robotics, AI, and implant technologies to empower interventional cardiologists worldwide.